Gilead Sciences Ranks 93rd in Trading Volume with $939 Million as ASCO Meeting Approaches

On May 15, 2025, Gilead Sciences (GILD) saw a trading volume of $939 million, ranking 93rd in the day's stock market activity. The company's stock price increased by 1.99%.

Gilead Sciences and its subsidiary Kite Pharma are set to present over 20 abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will cover a range of topics, including transformative data in first-line metastatic triple-negative breast cancer, updated results in multiple myeloma, and early data from various studies. This announcement is expected to draw significant attention from investors and analysts, as it highlights the company's ongoing efforts in cancer research and development.

Gilead and Kite's upcoming presentations at the ASCO Annual Meeting are anticipated to provide valuable insights into the efficacy and safety of their innovative therapies. The data to be presented includes transformative findings in first-line metastatic triple-negative breast cancer, which is a particularly aggressive form of the disease. Additionally, updated results in multiple myeloma and early data from other studies will offer a comprehensive view of the company's pipeline and its potential impact on the oncology market.